Τίτλος:
Immune response (IgG) following full inoculation with BNT162b2 COVID-19
mRNA among healthcare professionals
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Soon after the beginning of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic in December, 2019, numerous research
teams, assisted by vast capital investments, achieved vaccine
development in a fraction of time. However, almost 8 months following
the initiation of the European vaccination programme, the need for
prospective monitoring of the vaccine-induced immune response, its
determinants and related side-effects remains a priority. The present
study aimed to quantify the immune response following full vaccination
with the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine by
measuring the levels of immunoglobulin G (IgG) titers in healthcare
professionals. Moreover, common side-effects and factors associated with
IgG titers were identified. For this purpose, blood samples from 517
individuals were obtained and analysed. Blood sampling was performed at
a mean period of 69.0 +/- 23.5 days following the second dose of the
vaccine. SARS-CoV-2 IgG titers had an overall mean value of 4.23 +/-
2.76. Females had higher titers than males (4.44 +/- 2.70 and 3.89 +/-
2.84, respectively; P=0.007), while non-smokers had higher titers than
smokers (4.48 +/- 2.79 and 3.80 +/- 2.64, respectively; P=0.003). An
older age was also associated with lower antibody titers (P<0.001).
Moreover, the six most prevalent adverse effects were pain at the
injection site (72.1%), generalized fatigue (40.5%), malaise (36.3%),
myalgia (31,0%), headache (25.8%) and dizziness/weakness (21.6%). The
present study demonstrated that the immune response after receiving the
BNT162b2 COVID-19 mRNA vaccine is dependent on various modifiable and
non-modifiable factors. Overall, the findings of the present study
highlight two key aspects of the vaccination programs: First, the need
for prospective immunosurveillance studies in order to estimate the
duration of immunity, and second, the need to identify those individuals
who are at a greater risk of developing low IgG titers in order to
evaluate the need for a third dose of the vaccine.
Συγγραφείς:
Tsatsakis, Aristidis
Vakonaki, Elena
Tzatzarakis, Manolis and
Flamourakis, Matthaios
Nikolouzakis, Taxiarchis Konstantinos and
Poulas, Konstantinos
Papazoglou, Georgios
Hatzidaki, Eleftheria
and Papanikolaou, Nikolas C.
Drakoulis, Nikolaos
Iliaki,
Evangelia
Goulielmos, Georgios N.
Kallionakis, Manolis and
Lazopoulos, Georgios
Kteniadakis, Stelios
Alegkakis, Athanasios
and Farsalinos, Konstantinos
Spandidos, Demetrios A.
Περιοδικό:
International Journal of Molecular Medicine
Εκδότης:
SPANDIDOS PUBL LTD
Λέξεις-κλειδιά:
antibody titers; SARS-CoV-2; COVID-19; vaccination; BNT162b2 COVID-19
mRNA; IgG
DOI:
10.3892/ijmm.2021.5033
